The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting
predominantly the kidney and characterised by a triad of thrombocytopenia, mechanical …

Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …

Thrombotic microangiopathy can manifest in a diverse range of diseases and is
characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury …

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …

Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased
elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we …

The crosstalk among the complement system, immune cells, and mediators of inflammation
provides an efficient mechanism to protect the organism against infections and support the …

Eculizumab is the first and only medication approved for paroxysmal nocturnal
haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment …

Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a
common pathology, thrombotic microangiopathy, which is classically characterised by the …

Atypical hemolytic uremic syndrome (aHUS), a rare variant of thrombotic microangiopathy, is
characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal …